Presently, CD19 CAR T cells are approved for the treatment of refractory B-cell precursor acute lymphoblastic leukemia (B-ALL) and primary or relapsed diffuse large B-cell lymphomas [54,55]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.